The success of Ocrevus will help combat losses from Roche’s older stable of drugs, such as Herceptin and Rituxan, as cheaper biosimilar versions of these blockbusters are produced and brought to ...

MS drug Ocrevus has seen strong uptake as a high-efficacy ... Roche is already experiencing significant top-line pressure as key products Rituxan, Avastin, Herceptin, and Lucentis succumb to ...